Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 112 clinical trials
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer

The investigators hypothesize that low energy shock wave therapy (LESW) might induce damage to the tumor tissues of non-muscle invasive bladder cancer (NMIBC), so they could be ablated and

  • 27 Jan, 2021
  • 1 location
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

This study evaluates the tolerability and preliminary anti-tumour effect of alpha1H in adults with non-muscle invasive bladder cancer, who are awaiting transurethral surgery. In the main

  • 25 Jan, 2021
  • 1 location
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Bladder cancer is the fifth most common cancer in Canada and there has been relatively little progress in altering its clinical course over the last three decades. One of the major problems identified in the management of this disease, is under staging of muscle invasive disease which can lead to …

  • 26 Jan, 2021
  • 6 locations
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

tumor cells
expression by immunohistochemistry
bacillus calmette-guerin
carcinoma of the bladder
  • 25 Jan, 2021
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus-Calmette-Guerin

To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin

  • 01 Mar, 2021
  • 2 locations
Study of CG0070 Given in Combination With Pembrolizumab in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer

  • 27 Jan, 2021
  • 4 locations
Bacillus Calmette-Gu rin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to

  • 24 Jan, 2021
  • 10 locations
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized

  • 03 Feb, 2021
  • 2 locations
A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder

Previously-untreated, high-risk (>T3 and/or N+) muscle-invasive bladder cancer (MIBC) cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1

  • 23 Jan, 2021
  • 1 location
The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

placebo controlled trial. Outline: eligible patients with non-muscle invasive bladder cancer who undergo TURBT at our center will be randomized to receive either 40ml of normal saline or 40 ml of hypersal

  • 26 Feb, 2021
  • 1 location